April 29th 2025
Brett Casper explores the marketplace complexities that manufacturers face regularly.
April 16th 2025
The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.
March 12th 2025
The partnership focuses on enhancing the patient experience by providing greater affordability and access to specialty meds.
February 24th 2025
The injection for the treatment of psoriatic arthritis—among other indications—is a biosimilar to Stelara.
January 14th 2025
The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
Health plan managers seek more information on drug utilization
EMD Serono Specialty Digest finds they struggle over 'ensuring clinically appropriate use'
Avella pitches specialty pharmacy’s benefits in managing cancer care
Less drug waste, fewer ER visits can offset high drug costs
Survey tracks evolving health economics function in pharma
Cutting Edge report finds continued growth in headcount
Strategies for successfully commercializing innovative therapies in a changing environment
Pharma ups the ante on DTC advertising
Despite the buzz around digital media channels, pharma continues to pour marketing dollars into television
Another new hub services provider, with an emphasis on independence
Industry insider Nitin Sahney returns with PharmaCord
Leading independent pharmacy buying groups pair up
IPC and Pace Alliance will combine on April 1
Tracking a patient journey through integrated delivery networks (IDNs)
LexisNexis Health Care analyzes affiliation data on healthcare providers
Healthcare confronts opioid addiction
Drug-based therapies for opioid dependency gain acceptance and reimbursement
FDA issues guidances on biosimilarity naming, interchangeability
Interchangeability will require ‘switching studies’ and postmarketing surveillance
Supply chain is gobbling up more of pharmaceutical expenditures in the US
Brand manufacturers retain 47% of net expenditures for drugs
HDA Specialty Distribution 2016 report
More hospital, but fewer practitioner deliveries
For 15th straight year, nurses top Gallup poll of most trusted professions
Healthcare providers occupy top three slots
Lilly counters rising criticism of insulin drug prices with a PBM-driven, open-access discount
First branded-product discount program from Blink Health
QuintilesIMS drug spending outlook: $1.5 trillion in 2021, up 33%
Growth rates will moderate in the US and world
StayInFront expands its business-intelligence offering for life sciences SFA
Company offers to significantly undercut the pricing of sales force automation competitors
Knipper cuts the ribbon on new Indiana sample-fulfillment facility
Company approaches one million sq. ft. of warehouse capacity for pharma sampling programs
Putting drug administration in patient’s hands
Branded as MedStation, the device gives active guidance to seniors
Targeting the gatekeepers in long term care
The ‘age in place’ trend creates challenges for market access to seniors
Partnership offers ‘single view from factory to patient’ for specialty pharma
IntegriChain and ProMetrics combine resources for channel management
The fentanyl-opioid crisis is a counterfeiting crisis
More evidence that drug abusers are at risk from counterfeiters
Retail clinics are on a 26%/year growth trajectory, says Kalorama
Drug dispensing, point of care testing and diagnostics are beneficiaries
Avella Specialty Pharmacy tops list of fast-growing private pharmacies
Drug Channel’s analysis of Inc. 5000 shows some eye-popping growth
Much heat, little new light in Mylan’s Congressional hearing over EpiPen pricing
Mylan CEO sticks to authorized-generic strategy for price relief
Global pharma market will reach $1.12 trillion in 2022
Roche could overtake Novartis as the No. 1 global firm by then, says Evaluate Pharma
Drug pricing brawl turns to PBMs
Pharmacy benefit managers feel some marketplace heat even as they establish new benefit programs
Veeva touts its Events Management solution’s acceptance by Big Pharma
In first year, the product has six of Top 20 companies as clients
CVS Health continues focusing on the value of adherence
New study finds payer cost savings for patients with comorbidities
More analytics horsepower for defining prescriber profiles
Zephyr Health adds Referral and Segment Analytics to its Illuminate data service
When is a branded drug a generic? When it is sold by Mylan…
EpiPen controversy has a new twist: paying lower rebates to state Medicaid programs